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Genetic  mouse  models  for Alzheimer’s  disease  (AD)  have  been  widely  used  to understand  aspects  of  the
biology  of the  disease,  but have  had  limited  success  in translating  these  ﬁndings  to  the clinic.  In  this  review,
we  discuss  the  beneﬁts  and  limitations  of existing  genetic  models  and  recent advances  in  technologies
(including  high  throughput  sequencing  and  genome  editing)  that  promise  more  predictive  models.  We
summarize  widely  used  biomarkers  and  behavioral  tests  for mouse  models  of  AD  and highlight  best
practices  that  will  maximize  translatability  of preclinical  ﬁndings.
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. Introduction
With an aging population, Alzheimer’s disease (AD) is on the
ncrease with no current cures or effective treatments. Despite the
bvious advantages of using mice to study complex, age-related
iseases such as AD, it is a challenging time for mouse models. In
ome quarters, enthusiasm for using mice to model AD is wan-
ng, in part, because of the lack of success in translating ﬁndings in
ouse models to the clinic. Current models utilize knowledge from
arly onset Alzheimer’s disease (EOAD, or familial AD), incorporat-
ng mutant forms of amyloid precursor protein (APP), presenilins,
au (Mapt) and other genes. These models have been essential in
nderstanding the biology of key aspects of AD, most prominently
he formation of amyloid plaques and neuroﬁbrillary tangles, but
ave not proven particularly effective as preclinical models. Some
f this is down to the lack of the critical hallmarks of AD, notably
igniﬁcant neuronal cell loss, in the current models. However, the
ack of success is also due to a lack of standardization of models
such as inconsistent genetic background), underpowered experi-
ents, and less than ideal end points. Additionally, there may  be
igniﬁcant differences between early and late onset AD (LOAD, or
poradic AD) such that treatments tested in existing models may
e useful for EOAD but not for the sporadic form of AD that is much
ore common in the patient population.
Encouragingly, times are changing. Advances in studies of
atient populations and animal models should enable the cre-
tion of more predictive mouse models; these are summarized in
able 1 and described in detail below. Genome-wide association
tudies (GWAS), and more so high-throughput genome sequencing
rojects are identifying novel variants for late onset Alzheimer’s
isease that increase our knowledge of genetic susceptibility of
OAD (Fig. 1). Combine these advances with the revolution in
enetic and genome engineering and, although there is much work
till to do, the future looks bright for developing the next genera-
ion of AD models. In this review, we aim to provide recent updates
egarding current mouse models relevant to AD as well as consider
merging strategies for the generation of improved models. We
lso discuss how the ﬁeld is moving towards improved standards
or experimental design and phenotyping to maximize the beneﬁt
f mouse models as researchers seek novel therapeutic targets for
D.
. Modeling early-onset Alzheimer’s disease
Genetic mouse models of early-onset Alzheimer’s disease
ave been reviewed recently (Hall and Roberson, 2012) and are
ummarized in Table 2; we focus here on developments since
hen. A summary of existing AD mouse models is compiled and
aintained by the Alzforum (http://www.alzforum.org/research-
odels). This important resource includes updated information
egarding genetic construct, phenotype, and availability of each
ouse model.
While traditional transgenic mouse models have been essential
o our understanding of AD, they suffer from a variety of draw-
acks: mis- or over-expression of transgenically expressed protein
elative to the endogenous protein; developmental compensation
or knocked-out or over-expressed genes; and inadvertent and
nknown disruption of an endogenous gene by the transgenic con-
truct. Most transgenic lines have been created on standard genetic
ackgrounds, which may  not be the most suitable for expressing .  . .  .  . .  . . . .  . . .  . . . . . .  . . . . .  . . .  . . .  . . . . . . .  . . . . . . .  .  . .  . . . . .  .  . .  . . .  . .  . . .  .  . . . . . . .  .  . .  .  .  10
disease phenotypes (see discussion below). Perhaps most critically,
the timing of expression off the transgenic promoter will not mimic
the disease condition, so that mechanisms of disease onset cannot
be studied in a realistic context. In addition, the utility of many
of these models to the research community is limited due to legal
restrictions on their availability and use, particularly for therapy
development projects by for-proﬁt companies (Bubela and Cook-
Deegan, 2015).
Over the past few years, a variety of techniques have been used
to attempt to generate improved mouse models of EOAD. In order to
get away from the inherent technical issues with using traditional
transgenic models, some groups have used a knock-in strategy.
This has the advantage of providing more realistic expression pat-
terns and levels, and avoids the complication of disrupting an
unknown genomic locus. Perhaps due to the lack of over-expression
of APP and/or tau or the relatively short lifespan of the mouse,
these models have shown relatively mild, late onset phenotypes
(Malthankar-Phatak et al., 2012; Saito et al., 2014; Plucinska et al.,
2014).
Another recent approach to improving mouse models of EOAD
has been to use systems that enable inducible expression of
transgenic protein to study the half-life and reversibility of AD
endophenotypes. When mutant APP expression was turned off
after the formation of initial amyloid deposits, performance in some
cognitive tasks improved (Melnikova et al., 2013). Likewise, sup-
pression of transgenic mutant tau expression demonstrated that
tau-induced impairments are reversible (Van der Jeugd et al., 2012).
These studies provide justiﬁcation for drug trials in AD patients, at
least early in progression of the disease. A similar approach has been
used to distinguish the effects of soluble A relative to deposited
amyloid (Fowler et al., 2014).
In addition, a recent paper using genetic mouse models (Willem
et al., 2015) presents evidence that cleavage of the APP protein by
other than the well-known beta and gamma  secretase pathways
results in forms of A that may be important in APP pathology.
This highlights the fact that we still do not fully understand which
fragments of APP cause AD, and that genetic models are useful to
dissect the physiological cleavage events.
Various labs now are using a transcriptomics approach to com-
pare transcriptional proﬁles of mouse models to patient tissue,
with varying conclusions (Jackson et al., 2013; Landel et al., 2014;
Morihara et al., 2014; Burns et al., 2015).
One of the major beneﬁts to the mouse model is that it is rela-
tively easy to assay the effect of other genes/pathways to see if they
impinge on an established AD endophenotype. There have been
hundreds of publications showing that combining an existing AD
model with an established genetic knockout can modify a speciﬁc
phenotype (e.g., plaque load, performance in Morris water maze,
etc.). Most prominently, genetic ablation of the tau (Mapt) locus
in AD models has enabled dissection of the relative contributions
of the A and tau pathways to AD pathophysiology (Vossel et al.,
2015). While this approach may  be useful for identifying relevant
disease pathways and even targets, it has not led to a model that
recapitulates all aspects of the human disease.
3. Creating animal models for late-onset Alzheimer’s
disease
In contrast to creating mouse models for EOAD, generating mod-
els for late-onset Alzheimer’s disease (LOAD) is more challenging.
K.D. Onos et al. / Brain Research Bulletin 122 (2016) 1–11 3
Table  1
Summary of recent advances that will aid generation of more predictive models.
Advances Examples
A. Advances in human
AD characterization
1. Identiﬁcation of speciﬁc AD-relevant
variations in genes using high throughput
sequencing
(i) Trem2
(ii) Abca7
(iii) Bin1
2.  Improvements in ‘staging’ of AD (i) In vivo imaging
(ii) Blood cell proﬁling
3.  Emerging clinical endophenotypes (i) Neuroinﬂammation
(ii) Vascular compromise
(iii) Associated behaviors (e.g. sleep disruption,
depression, seizures)
B.  Advances in mouse
modeling
1. Genetic background (i) Standardization and deep characterization
of traditional strains
(ii) Generation of genetically-diverse inbred
(Collaborative Cross) and outbred (Diversity
Outbred) strains
2.  Incorporation of environmental factors (i) Diet
(ii) Physical activity
(iii) Microbiome
3.  Computational modeling (i) Gene:gene interactions
(ii) Gene:environment interactions
4.  Genome engineering (i) CRISPR
(ii) TALENs
5. Phenotyping (i) A and Tau oligomer species (e.g. A*56,
TOC1)
(ii) Myeloid cell characterization (Microglia vs.
Macrophage, e.g. Trem2, Ly6c, CB2, tmem119)
(iii) Markers of neuronal/synaptic dysfunction
(e.g. DCX, Cr2)
(iv) See Table 3 for behavior
Fig. 1. Known and Predicted Protein–Protein Interactions (STRING) of the top 48 LOAD genes. The current top 48 LOAD genes compiled by ALZFORUM (Bertram et al., 2007).
Highlighted red nodes are related with the key word ‘neuroinﬂammation’.
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Table 2
Summary of prominent mouse models of Alzheimer’s disease.
Type Model Promoter Allele(s) Allele Type Lab # PubMed citations Repository
availability;
relative interest
Amyloid, Tau 3XTg-AD Thy1 APP(Swe), Mapt(P301L);
Psen1(M146V)
Transgenic (cDNA); KI LaFerla 702 JAX #4807 ***
Amyloid APP/PS1 Prnp APP(Swe); Psen1dE9 Transgenic (cDNA) Borchelt 207 JAX #5864, #4462 ***
Amyloid 5XFAD Thy1 APP(SweFlLon);
PSEN1(M146L; L286V)
Transgenic (cDNA) Vasser 277 JAX #8730, #6554 ***
Amyloid J20 PDGFB APP(SweInd) Transgenic (cDNA) Mucke 394 JAX #6293 **
Amyloid Tg-SwDI Thy1 APP(SweDutIowa) Transgenic (cDNA) Van Nostrand 90 JAX #7027 *
Amyloid Tg-SwDI/Nos2 Thy1 APP(SweDutIowa); Nos2
KO
Transgenic (cDNA) Van Nostrand 20 JAX #9126 *
Amyloid Tg2576 Prnp APP(Swe) Transgenic (cDNA) Ashe 800 Taconic; Charles River
Amyloid R1.40 APP APP(Swe) Transgenic (YAC) Lamb 18 JAX #5300 *
Amyloid APPPS1 Thy1 APP(Swe) Transgenic (cDNA) Jucker 101 NA
Amyloid APP23 Thy1 APP(Swe) Transgenic (cDNA) Novartis 216 Novartis
Amyloid PDAPP PDGF APP(Ind) Transgenic (cDNA) Games 270 NA
Amyloid APP NL-G-F APP APP(SweIbeArc) Knock-in Saido 14 NA
Amyloid TgCRND8 Prnp APP(SweInd) Transgenic Westaway 182 NA
Tau  rTg4510 X Camk2a-tTA Camk2a MAPT(P301L) Inducible transgenic Ashe/Hutton/Lewis 363 JAX #24854 ***
Tau  hTau MAPT MAPT; Mapt KO Transgenic Davies 128 JAX #5491 **
Tau  PS19 Prnp MAPT(P301S) Transgenic (cDNA) V. Lee 250 JAX #8169 **
Tau  rTg4510 X Nop-tTA Nop MAPT(P301L) Inducible transgenic Hyman 207 JAX #15815 *
Other  GFAP-apoE4 GFAP APOE Transgenic (cDNA); KO Holtzman 29 JAX #4631 *
Other  Apoetm3(APOE*4) Apoe APOE Targeted replacement Maeda 53 Taconic
# ing th
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a PubMed citations is the number of papers that have cited the initial paper describ
nterest  is a representation of the number of orders received by the JAX mouse repo
his is mainly due to the complex genetic and environmental fac-
ors (diet, physical activity, microbiome, etc.) that interact to cause
OAD, many of which remain undiscovered. Currently, very few
peciﬁc genetic variations are known to increase risk for LOAD. The
wo that have garnered the most interest for AD are the 4 allele of
polipoprotein E (APOE), a common variant and the R47H allele of
he triggering receptor expressed on myeloid cells 2 (TREM2) gene,
 rare variant. Both variants greatly increase the risk of developing
D.
.1. APOE—the greatest genetic risk factor for AD
The 4 allele of the apolipoprotein E (APOE4) gene is the great-
st genetic risk factor for AD, with the 3 allele (APOE3) considered
eutral and the 2 allele (APOE2) considered protective. In human
rains, APOE is normally synthesized and secreted by astrocytes
nd binds to high-density lipoproteins to facilitate cholesterol and
hospholipid transport to LDL receptors. Low plasma APOE and
POE4 genotype are associated with morphological changes to the
ippocampus, speciﬁcally reductions in size (Shi et al., 2014; Teng
t al., 2015). Mouse models for studying both Apoe function and
he human APOE variants have been created and have highlighted
 complex role for APOE in the aging and diseased brain. Mice either
eﬁcient in Apoe or carrying the APOE4 ‘humanized’ allele in place
f the mouse Apoe gene show a variety of phenotypes including
eﬁcits in cholesterol trafﬁcking, amyloid clearance and the blood
rain barrier integrity. Importantly, mice heterozygous or homozy-
ous for human APOE4 do not develop the complete AD phenotype
howing that additional genetic and/or environmental factors are
equired.
.2. TREM2—elevating the signiﬁcance of immune responses in
D
A genome-wide association study (GWAS) identiﬁed the R47H
ariation in TREM2 that conferred increased risk for AD (Guerreiro
t al., 2013), and more recently, a group at Brigham and Women’s
ospital found higher cortical TREM2 RNA expression was  associ-
ted with increased amyloid pathology, suggesting a pathogenice strain; it is not meant to indicate how many times a strain has been used. Relative
 KO, Knock-out; KI, Knock-in; NA, not applicable; YAC, yeast artiﬁcial chromosome.
role of TREM2 in AD susceptibility (Chan et al., 2015). Highlighting
the importance of TREM2 in neurodegenerative diseases more gen-
erally, some studies have also associated variations in TREM2 with
Parkinson’s disease (Benitez et al., 2013), frontotemporal dementia
(Rayaprolu et al., 2013; Borroni et al., 2014) and amyotrophic lateral
sclerosis (Cady et al., 2014). These discoveries led to a series of stud-
ies in mice to understand the relevance of TREM2 variations to AD.
First, APP/PS1 mice haploinsufﬁcient for TREM2 (carrying only one
copy) showed an altered microglial response without impacting
plaque load (Ulrich et al., 2014). Second, deﬁciency of TREM2 pre-
vented inﬁltration of blood-derived myeloid cells and ameliorated
plaque burden in APP/PS1 mice (Jay et al., 2015). Finally, deﬁciency
or haploinsufﬁciency of TREM2 augment amyloid accumulation
due to a dysfunctional microglial response (Wang et al., 2015). By
generating R47H expressing reporter cells, the study showed that
the R47H mutation impairs the ability of TREM2 to recognize lipid
ligands. There is much still to learn about the role of TREM2 in
AD and so the generation of mice carrying human forms of TREM2
(including the R47H variant) is essential.
3.3. The strengths and limitations of genome-wide association
studies
Beyond APOEε4 and TREM2R47H , although much effort has been
directed towards identifying additional speciﬁc genetic variants,
little progress has been made, making modeling genes relevant to
LOAD particularly challenging. However, large GWAS have identi-
ﬁed multiple loci that increase risk for AD. For instance, one study
that included approximately 75,000 individuals identiﬁed as many
as 21 loci. The limitations of GWAS are that they commonly iden-
tify loci that are predicted to confer a small increase in risk and do
not normally identify the causative variant, merely the haplotype
block in which the causative risk variant is located. For each locus,
the gene(s) that lie closest to the most strongly associated variant(s)
become associated with the disease and for AD include complement
receptor 1 (CR1), bridging integrator 1 (BIN1), clusterin (CLU) and
Phosphatidylinositol-binding clathrin assembly protein (PICALM).
A recent paper sought to control for this confound by using targeted
sequencing of GWAS loci and identiﬁed an excess burden of dele-
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concerns over the use of behavioral endpoints with animal mod-
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erious coding mutations, speciﬁcally in relation to ATP-binding
assette sub-family A member 7(ABCA7) and BIN1 (Vardarajan et al.,
015).
Genes associated with LOAD are anticipated to function in
athways thought to be important in AD including cholesterol
etabolism, endocytosis and immune responses. The lack of
ausative variants for these genes provides particular challenges
or modeling in mice. Using traditional resources, the mouse is con-
inuing to play a critical role in understanding the biology of genes
ssociated with LOAD. Commonly, mutations in associated genes
re introduced to AD mouse models and the impact of either hap-
oinsufﬁciency or complete deﬁciency on AD-relevant phenotypes
etermined. While incredibly informative in terms of associating
enes/pathways with different aspects of AD, these types of exper-
ments do not necessarily get at the underlying causes of why
ariations in genes/loci confer increased risk for AD.
The challenges of interpreting GWAS ‘hits’ are not unique to
D, but are being discussed for other genetically complex diseases
ncluding diabetes. Given the majority of GWAS hits lie outside
oding regions, it is anticipated that these small effects are due
o variations in non-coding regions such as regulatory elements
hat may  impact the dosage of transcripts rather than the protein
unction directly. This has led researchers to propose systematic
aploinsufﬁciency studies, whereby one copy of each GWAS gene is
utated and the effects on AD phenotypes evaluated. Given suscep-
ibility to LOAD is likely due to variations affecting multiple genes it
ill be necessary to assess perturbations in pairs or groups of genes
o understand how genetic variations interact to increase risk for
D.
.4. Developing human-relevant mouse models for LOAD
Ultimately, major breakthroughs in modeling LOAD in mice will
ome from the identiﬁcation of additional speciﬁc genetic varia-
ions that increase (or decrease) risk for AD. Therefore, major efforts
o identify causative variants continue. These have been greatly
acilitated by the development of high throughput sequencing,
llowing for large scale sequencing of exomes and genomes from
D patients and unaffected controls. For instance, the Alzheimer’s
isease sequencing project (ADSP) is sequencing more than 600
hole genomes from a family-based study and more than 10,000
xomes from AD cases and controls. Coupled with large-scale
equencing studies are large-scale clinical based studies such as
he Alzheimer’s disease neuroimaging initiative (ADNI) that aims
o develop clinical, imaging, genetic and biochemical biomarkers
or the early detection and tracking of AD. Information coming out
f projects such as ADSP, ADNI and the Accelerating Medicines Part-
ership (AMP) should greatly facilitate the development of the next
eneration of mouse models for LOAD, ensuring that new models
re as human-relevant as possible.
. Maximizing the power of genome engineering and
enetics to model AD in mice
We  are in the middle of a revolution in mouse-based research
ecause of the development of (i) high-throughput sequencing
romising the identiﬁcation of increased numbers of candidate
ausative variants for human diseases, (ii) genome engineering
echnologies allowing for development of engineered mice in
onths not years at a fraction of the cost, and (iii) the develop-
ent of new generations of inbred and outbred mice that allowor more precise identiﬁcation of genes and variants that impact
isease phenotypes. Collectively, these advances are likely to play
 crucial role in understanding AD pathogenesis and in generating
mproved mouse models for preclinical testing.Bulletin 122 (2016) 1–11 5
4.1. Genome editing with CRISPR
The discovery that naturally existing nucleases such as CRISPRs
(Sander and Joung, 2014) can alter individual bases, often termed
‘genome editing’, means that genetically engineered mice can
be created efﬁciently and cost effectively. Further advances are
expected that will include incorporating larger stretches of DNA
enabling replacement of human gene sequences to the corre-
sponding mouse locus (humanizing the mouse) and generating
conditional alleles and new cre driver lines to study the temporal
and spatial function(s) of genes. Thus, candidate variants can read-
ily be assessed in mice by genome editing. Given that LOAD is likely
caused by variations in multiple genes, it is critical that genome
editing allows the introduction of multiple variants simultane-
ously. Therefore, future mouse models for LOAD based on human
sequence variation should have greatly improved utility for pre-
clinical and translational studies. These strategies can complement
genetic manipulation strategies in human tissues/cells including
the ability to assess variants in speciﬁc cell types derived using
induced pluripotent stem cells (IPSCs) (Ding et al., 2014; Tucker
et al., 2014).
4.2. Identifying genetic modiﬁers using inbred and outbred
mouse populations
The majority of mouse models for AD exist on one or only a few
genetic backgrounds. Previous studies have shown that modifying
the genetic background can have signiﬁcant impact on AD-relevant
phenotypes. However, systematic assessment of AD mutations on
the most genetically diverse mouse strains (including wild-derived
strains such as CAST/EiJ) has not been performed. Also, a major
limitation of using quantitative trait loci (QTL) mapping is the lack
of power to identify speciﬁc variations that affect the phenotype.
More often, a large genetic interval was  identiﬁed. This disadvan-
tage has led to the development of new, genetically diverse inbred
mouse strains (Collaborative Cross, CC) and genetically unique out-
bred strain (Diversity Outbred, DO) (Churchill et al., 2012). CC and
DO mice capture the greatest amount of genetic diversity currently
available in mice, so studies using DO mice greatly reduce the size of
QTL loci and therefore the number of candidate variants for further
testing (Yang et al., 2011; Svenson et al., 2012). As mouse models for
AD improve, DO and CC strains hold great promise for identifying
genetic modiﬁers that can be tested as novel therapeutic targets.
5. Improving reproducibility of existing and the next
generation of mouse models
The majority of current animal models of AD develop amy-
loidosis and tauopathy and therefore much of the molecular
and physiological phenotyping methods surround APP and tau
pathology. Indeed, the most stable and commonly used biomark-
ers used in human patients today are CSF measurements of
A42/A40 and p-Tau/t-Tau; these have been reviewed pre-
viously (Rosen and Zetterberg, 2013; Blennow et al., 2015).
However, additional pathologies may  be critical in the devel-
opment of AD and include neuroinﬂammation, neurogenesis
disruption, and vascular dysfunction that should be considered in
the phenotypic assessment of AD models. Also, due to the recentresearch-summit-2015), we  conclude this section with recommen-
dations for best practices in behavioral testing to address issues of
reproducibility and clinical translatability.
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.1. Amyloidosis and tau pathology
Current mouse models of AD have been successful at separately
odeling amyloidosis and tau pathology. As discussed earlier, these
odels are necessary to understand early drivers of amyloidosis
nd tau pathology, especially when study design takes into account
isease relevant changes in the context of normal aging. This is par-
icularly highlighted with the early success of aducanumab, a drug
eveloped by Biogen that binds to and reduces amyloid plaques
n human cases. Much of the success of aducanumab trials com-
ared with other failed amyloid targeting drugs may  be related
o better identiﬁcation of individuals in the early stages of AD and
arly treatment with the drug. Regardless, this has caused renewed
nthusiasm for amyloidosis inhibiting therapies.
However, the relationship between amyloidosis and tau pathol-
gy remains elusive, and improved models in this domain are
ssential. The amyloid cascade hypothesis is not limited to the
ccumulation of A plaques, but includes oligomeric aggregates as
hese appear to be better correlated to early memory impairments
nd severity of dementia (Broersen and Rousseau Schymkowitz,
010). Recent research has shown that A oligomers prompt tau
ligomerization (Lasagna-Reeves et al., 2010). One such species,
*56, has been hypothesized to be a molecular trigger of disease
nset and is shown to be correlated with levels of total tau and
hosphorylated tau in those with an elevated risk for developing
D (Handoko et al., 2013). Presence of A*56 in AD mouse models
as been variable, though when present or injected it is correlated
ith strong memory deﬁcits. Mice treated with anti-tau oligomer-
peciﬁc monoclonal antibody show reduced levels of A*56 and
how improved performance on memory tasks, hinting at a direct
nteraction between A and tau (Castillo-Carranza et al., 2015). The
iffuse dispersal of A*56 throughout many brain regions may  lead
o a more substantial impact on synaptic function and morphol-
gy in comparison with the high degree of plaque localization of
 dimers (Zahs and Ashe, 2013). This highlights the importance
f characterization and localization of processed and unprocessed
 aggregates in current and future AD models. In order to under-
tand the true potential of amyloidosis-inhibiting therapies it is not
nly critical to target A in preclinical stages, but equally impor-
ant to target the appropriate A species. The use of more diverse
ouse genetic backgrounds in amyloidosis modeling may  uncover
et unknown forms of A that may  also contribute to disease onset
nd severity.
Amyloid reduction therapies have been shown to lead to the
ndesired increase in tau phosphorylation as a consequence, and
he inverse is also true: antagonism of tau phosphorylation also
esults in an increase in amyloidosis (Castillo-Carranza et al., 2015;
oppel et al., 2014). Earlier this year Calafate et al. (2015) demon-
trated in vitro neuron-to-neuron transmission of tau across the
ynapse (Calafate et al., 2015). Decreases in synaptic density or
ctivity appeared to weaken this propagation and this suggests that
herapies focused on promoting synaptogenesis in later stages of
D should be discouraged. While it remains to be conﬁrmed in vivo,
his study emphasizes importance of understanding the dynamic
inetics of neurodegenerative proteins. The decrease or downregu-
ation of a particular cell product or type may  in fact be a protective
echanism rather than simply the consequence of disease.
In a similar vein, much research has focused on how the brain
ormally clears toxic byproducts. The pathways through which
 and tau are removed from the brain constitute the glymphatic
ystem-cerebral arteries create a convective force allowing CSF
o circulate inside the parenchyma along arterial walls where it
ncounters interstitial ﬂuid and ﬂushes interstitial proteins. As
emonstrated using a genetic knock-out in a mouse model, this
ystem is strongly dependent on the water channel aquaporin-4
ocated in astrocytic end feet (Iliff et al., 2012). Reductions in the Bulletin 122 (2016) 1–11
efﬁciency of the glymphatic system are seen with age as pulsatil-
ity of arteries wanes and localization of the aquaporin-4 receptor
becomes more erratic (Jessen et al., 2015). A strong relationship
between glymphatic system function and sleep and wake cycles
has also been established. In a now seminal paper, researchers
at the Center for Translational Neuromedicine were able to use
two-photon imaging in live mice to demonstrate a 60% increase
in interstitial space while the animals were engaged in sleep or
under the inﬂuence of anesthesia, suggesting that clearance of
neuronal waste is enhanced during sleep (Xie et al., 2013). This
is further supported by work that shows that levels of A follow
a diurnal pattern: A40 and A42 levels are higher in the CSF
in non-diseased young individuals during wakefulness and lower
during sleep (Huang et al., 2012). Thus, changes to sleep duration
could impact the ability of the brain to effectively expel protein
aggregates. Disruptions in sleep patterns are also a common com-
ponent of aging (Crowley, 2011; Pace-Schott and Spencer, 2011),
and this paired with the decreased efﬁciency of the glymphatic
system could contribute to disease pathology. This relationship
becomes more complex as recent work demonstrated that A
exerts direct effects on sleep, speciﬁcally on non-rapid eye move-
ment slow wave sleep (NREM SWS). NREM SWS  is associated
with long-term hippocampus-dependent memory consolidation;
therefore the accumulation of A may  indirectly contribute to
memory impairments through disruption of NREM SWS  (Mander
et al., 2015). Sleep disturbances also trigger a neuroinﬂammatory
response, which with age-related alterations in immune func-
tion can lead to persistent neuroinﬂammation (Wisor and Schmidt
Clegern, 2011).
5.2. The emergence of neuroinﬂammation as a key component of
Alzheimer’s disease
Convincing evidence from both pathological and genetic stud-
ies shows neuroinﬂammation plays a key role in the susceptibility,
onset and progression of AD pathology. At the forefront of this
response is the activation of astrocytes and microglia. While the
short-term release of inﬂammatory cytokines, chemokines and
activation of the complement system by these cells is beneﬁcial and
neuroprotectant, long-term activation and proliferation can lead
to neuronal damage. Recent studies suggest chronic neuroinﬂam-
mation could be a key contributing factor to neurodegenerative
features of AD. However, it is important to note that an increase
in neuroinﬂammation with age is normal and as AD is tightly cou-
pled to aging, it is important to elucidate these processes in parallel
(Mosher and Wyss-Coray, 2014).
Of late there has been renewed interest in the role of microglial
receptors such as cannabinoid receptor 2 (CB2) in AD. Studies have
focused on the utility of CB2 as a biomarker of A-related inﬂam-
mation, particularly in early stages of disease progression prior to
signiﬁcant neuronal loss (Savonenko et al., 2015). Increased expres-
sion of CNR2, the gene that encodes CB2 receptor, is present in AD
brains along with increased CB2 expression in plaque-associated
microglia, and expression levels are also correlated with cognitive
decline (Solas et al., 2013; Grunblatt et al., 2009). This is also seen in
patients with Down’s syndrome-associated A amyloidosis (Nunez
et al., 2008). This phenotype is present in AD mouse models. CRN2
KO mice show an increase in amyloidosis and alterations in tau pro-
cessing that led to a decrease in measures of total tau (Koppel et al.,
2014). Taken together, this suggests that CB2 should be considered
as a marker of neuroinﬂammation.
5.3. Neuronal dysfunction/loss— a key hallmark missing in
current Alzheimer ’ s disease models
As was  mentioned previously, while AD is a disorder charac-
terized by neuronal degeneration, there are currently no animal
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odels that demonstrate signiﬁcant neuron loss. Therefore, a major
oal is to generate mouse models that develop signiﬁcant neuronal
athology such as synaptic and axonal dysfunction/loss. Regions of
he cortex, particularly the entorhinal cortex, and the hippocampus
re some of the earliest brain regions to be affected in human AD.
he hippocampus includes the dentate gyrus, CA1, CA2, and CA3
elds and subiculum. A plethora of animal lesion and inactivation
ork along with human case studies have established the critical
ole of this structure in learning and memory processes; thus, early
D symptoms of memory loss can be attributed to hippocampal dis-
uption. In fact, two of the earliest changes reported are to the two
ajor underlying sources of hippocampal plasticity: neurogenesis
nd long-term potentiation (LTP) (Poirier et al., 2010).
Impairments in adult neurogenesis have been reported in
uman AD cases (Ziabreva et al., 2006; Winner et al., 2011), and
lterations appear to be mutation-speciﬁc in murine models. Some
odels such as the J20 line show increased neurogenesis but sig-
iﬁcant impairments in LTP. Other models such as APP/PS1 mice
howed a decrease in both neurogenesis and LTP (Crews and
ockenstein Masliah, 2010). It is important to note that while
eurogenesis and LTP appear to be intimately linked, blockade of
eurogenesis impairs dentate gyrus LTP only for a limited time-
estoration of LTP is observed within 6 weeks despite the continued
bsence of neurogenesis (Singer et al., 2011).
Many of the newly identiﬁed genes for LOAD are involved in
euroinﬂammation, which directly impacts neurogenesis and LTP
Fuster-Matanzo et al., 2013). Work by Moriyama et al. (2011)
ocalized complement receptor 2 to the surface of neural progen-
tor cells (Moriyama et al., 2011). Cr2 −/− mice have a signiﬁcant
ncrease in immature neuroblasts and 40% increase in mature neu-
ons, suggestive that the role of Cr2 is to dampen adult hippocampal
eurogenesis. Neural stem cell populations are also inﬂuenced by
ndocannabinoid signaling; upregulation of CB1 and CB2 activ-
ty stimulate adult hippocampal neurogenesis, whereas inhibition
educes it (Di Marzo et al., 2015). More research is necessary to
lucidate the role of endocannabinoids in AD-related impairments
n neurogenesis. Regardless, markers of neurogenesis such as bro-
odeoxyridine (BrdU), doublecortin (DCX) and calretinin (CALB2)
hould be considered in the characterization of all AD mouse mod-
ls.
.4. Vascular dysfunction
Historically, vascular dysfunction has not been included as part
f the pathology of AD, with vascular dementia being considered a
ifferent form of dementia to AD. More recently, strong evidence
upports a key role of vascular disruption in AD and therefore
s an important area to study in mouse models. The double hit
ypothesis for AD has been proposed whereby vascular dysfunc-
ion precedes and promotes amyloid toxicity. In support of this,
poe deﬁciency or mice carrying a human APOE4 transgene can
how a disrupted blood brain barrier (Methia et al., 2001; Bell et al.,
012). APOE4 is proposed to induce the activation of the proinﬂam-
atory cyclophilin A (CypA)—matrix metalloproteinase 9 (MMP-9)
athway in brain pericytes leading to the breakdown of the BBB and
eurodegeneration. A recent study from our lab shows that vascular
ysfunction, including basement membrane breakdown, pericyte
oss and vascular leakage, occurs in the cortex and hippocampus of
ging mice (Soto et al., 2015). Although more work is needed, data
upport a role of astrocytic APOE whose expression declines with
ge, possibly as a result of astrocyte senescence. Vascular dysfunc-
ion was prevented by exercise, suggesting a possible mechanism
y which these types of treatment paradigms may  delay AD onset
r slow progression.
Further evidence for vascular dysfunction in AD came from
WAS study that showed that copy number variations in mes-Bulletin 122 (2016) 1–11 7
enchyme homeobox 2 (MEOX2), a gene involved in vascular
development, are associated with severe forms of AD (Wu  et al.,
2005). Mice carrying only one copy of Meox2 also have altered
vasculature. Therefore, blood–brain barrier disruption needs to be
considered in current and future models of AD.
The neuro-vascular unit comprises multiple cell types including
astrocytes, pericytes and endothelial cells. Complex communica-
tions between these cell types are required for the development
and maintenance of a healthy neurovascular unit (Obermeier et al.,
2013) and disruption of even some of them can lead to a dysfunc-
tional vasculature. Importantly, there is an intimate relationship
between neurovascular health and neuroinﬂammation, including
immune cell inﬁltration, and mouse models can facilitate a better
understanding of these processes.
5.5. Improved Translation of mouse models for Alzheimer’s
disease
A tiered phenotyping approach should be employed for eval-
uating mouse models of Alzheimer’s disease that are not solely
limited to the primary endpoint (e.g. cognitive measures) but
also includes evaluations of general locomotor and exploratory
behaviors, measures of disease progression which encompass typ-
ical age-related impairments such as vision, hearing, ﬁne motor
skills, and metabolism, and co-morbidity phenotypes related to
AD such as anxiety, depression, motivation, and sleep disturbances
(Table 3 and Fig. 2). Importantly, behavioral endpoints that could be
inﬂuenced by another competing behavior should be well charac-
terized; hence the need for activity measures independently (e.g.,
open ﬁeld assessment) and as a measurable endpoint within assays
that require an activity dependent measure. For example, the typ-
ical battery of cognition tests used to evaluate mouse models of
AD (i.e., water maze, fear conditioning, y-maze) are motor based
assays and it is crucial to ensure that alterations in activity levels in
the disease model relative to the WT  control is not driving any per-
ceived cognitive deﬁcit. Speciﬁcally, hyperactivity which has been
reported to be observed in a number of AD mouse models (Rodgers
et al., 2012) may  be the main reason for mice not being capable of
the freezing response required to demonstrate intact memory in a
fear conditioning assay. Further, mice should be tested for visual
impairments to ensure that deﬁcits in cognitive tests that employ
visual cues are not confounded by impaired visual acuity that may
be a known factor dependent upon background strain, but should
not be ruled out in the mutant relative to its WT control (reviewed
in (Hall and Roberson, 2012)).
In order to improve the translational utility of animal mod-
els, the preclinical strategy should be designed in parallel to the
clinical strategy. For example, if clinical trials will not be employ-
ing spatial learning memory as part of the functional assessment
in patients, then results in the water maze may  not be useful. It
has been reported that some of the earliest deﬁcits observed in
AD patients when pathology is likely minimal are impairments
in episodic memory (reviewed in (Webster et al., 2014)). Recent
development of behavioral assays that speciﬁcally assess episodic
memory may  be of greater value than traditional rodent learning
and memory tasks such as fear conditioning and water maze, which
may  only be impaired as disease has progressed signiﬁcantly in
the mouse model, to the point that deﬁcits in these tasks may be
confounded by deﬁcits in motor and physiology. New technologies
for cognitive assessments in rodents using touchscreen technology
provide improved translation from mouse to man and include tests
for attention, learning, and memory. This advanced technology for
assessing cognitive measures in animal models not only includes
similar visual cues that can be used across species, but also the
similar tactile responses used in the clinic (i.e., touchscreen tablets
or iPads) (Bussey et al., 2012; Romberg et al., 2013, 2011). These
8 K.D. Onos et al. / Brain Research Bulletin 122 (2016) 1–11
Table 3
Relevant assays for comprehensive phenotyping of mouse models of Alzheimer’s disease.
Behavioral domain Assay
Motor, coordination, &
strength
Locomotor activity—open ﬁeld
Gait—treadmill or spontaneous walking
Coordination—accelerating rotarod
Strength—grip strength
Cognition Learning & memory—water maze
Learning & memory—contextual fear conditioning
Learning & memory—visual discrimination & reversal task (touchscreen)
Learning & memory- paired associates learning task (touchscreen)
Learning & memory—baited holeboard task
Memory—novel object or novel spatial recognition task
Spatial working memory—spontaneous alternation
Episodic memory—episodic memory task
Attention—5 choice serial reaction time task
Disease progression Vision—electroretinography
Visual acuity—optokinetics
Hearing—auditory brainstem responding
Hearing—acoustic startle response
Fine Motor—adhesive removal test
Metabolism—indirect calorimetry
Blood pressure monitoring
Bone densitometry (DEXAscan)
Co-morbidity
phenotypes
Anxiety—light/dark test
Anxiety—stress-induced hyperthermia assay
Anxiety—elevated zero or plus maze
Depression—forced swim test
Depression—tail suspension test
Social behavior
Motivation—progressive ratio responding
Motivation—sexual behavior
Circadian activity—wheel running
Sleep—EEG
Fig. 2. A tiered longitudinal phenotypic assessment.
K.D. Onos et al. / Brain Research Bulletin 122 (2016) 1–11 9
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echnologies are not without their limitations however, as the test
ubjects require weeks to months of testing, food restriction for
eward motivation, and to date it remains unknown whether the
ouchscreen tests have predictive validity.
.6. Reproducibility
The ongoing criticisms of the lack of ability to reproduce scien-
iﬁc data has been a frustrating reality; in particular to those who
re experts in the ﬁeld of behavioral neuroscience and who can
ecognize the lack of important environmental and experimental
etails not described in the initially reported datasets (van der Staay
nd Steckler, 2002; Steckler, 2015). While criticisms have often
ocused on those that are unable to reproduce the initial discov-
ry, it is just as likely that the originally published datasets were
ot necessarily produced under the optimal conditions or with the
ppropriate controls that deem it reproducible in the ﬁrst place;
otwithstanding the lack of critical details published in the meth-
ds sections (Steckler, 2015; Kilkenny et al., 2009, 2010; Landis
t al., 2012; Steward and Balice-Gordon, 2014). Poorly conducted
ehavioral studies often performed by minimally experienced sci-
ntists with limited training in behavioral pharmacology, driven by
ressures to provide functionally translational and relevant end-
oints for molecular ﬁndings often leads to rushed experiments
ithout proper controls and optimized testing conditions (Unger,
007). Furthermore, similar to the way clinical trials are care-
ully planned, preclinical studies for drug discovery need to follow
 similar planning process including predetermined sample size,
linding, randomization, counterbalancing, and the inclusion of
ppropriate controls. The piecing together of several small under-
owered experiments to achieve the desired results, typically by
dding in subjects to treatment groups retrospectively when the
nitial experiments did not in themselves yield statistical signiﬁ-tional utility of preclinical models.
cance independently of each other, is not an acceptable practice
for a clinical trial design and is also not acceptable for preclini-
cal studies (Landis et al., 2012; Unger, 2007). While pilot studies
with small sample sizes are helpful to inform power calculations
for follow up experiments, separate appropriately powered exper-
iments should be planned and then reproduced to conﬁrm positive
outcomes in an independent cohort (Sukoff Rizzo, 2015). Impor-
tantly, behavioral tests should be conducted by highly experienced
technicians proﬁcient in conducting sensitive behavioral studies
under blinded conditions and considerations should be made for
second site or cross laboratory conﬁrmation to ensure conﬁdence
and reproducibility.
5.7. Improving Clinical Translation
To date there remains a gap in the translatability of preclinical
data. While more rigorous experimental designs are an important
requirement, a clear understanding of the experimental compound
being evaluated, and more speciﬁcally its pharmacokinetic and
pharmacodynamic properties will inform the selection of a relevant
and target speciﬁc dose range, as well as an optimal pretreatment
time and route of administration (reviewed in (Rizzo et al., 2013)).
It is also important to not overly interpret the data generated
in animal models. As previously noted, many AD mouse models
have been reported to demonstrate “cognitive impairments” which
may  be confounded by hyperactivity in those models. A dose of
an experimental compound that is mildly sedative may  normalize
the hyperactivity in the mouse, unmasking its ability to success-
fully perform the cognitive task. Data should therefore be carefully
interpreted, ensuring that the dose range is speciﬁc to the target
(e.g., based on receptor occupancy studies or correlative biomarker
data). Furthermore, in addition to the dose range of the compound
that produces the therapeutic effect, it is critically important to
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lso identify the compound’s therapeutic window, and the dose
ange at which non-speciﬁc effects occur that may  be adverse or
hich could confound the interpretation of the behavioral response
Fig. 3).
. Conclusions
While results in AD mouse models to date have not been shown
o have high predictive validity, there are reasons to believe that
ould be changing. Improved understanding of the genetics of
poradic AD along with better tools for manipulating the mouse
enome should lead to mouse models with improved construct
alidity, and the use of assays that more closely replicate those
sed in clinical trials (along with the use of biomarkers in common
etween the models and patients) should lead to better measures
f face validity.
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